New study provides insight into anti HRV drug development

Scientist Angus MacLeod and his colleagues reported last week that progress has been made in the search for the first effective vaccine against human rhinoviruses.

HRV is responsible for causing the most common infectious diseases in the world. Although most symptoms of the diseases the virus cause are mild, it can cause severe complications for anyone with asthma and chronic obstructive pulmonary disease. Previous drugs that held promise for combating HRV proved to be ineffective or caused severe side effects, spurring MacLeod and his team of researchers to develop an effective drug to combat HRV.

The study, reported in the ACS Medicinal Chemistry Letters journal, discovered a group of compounds that show promise towards combating HRV. MacLeod and his team of researchers reported the compounds seem successful in fighting HRV, Coxsackie virus, poliovirus and enterovirus-71. The compounds work by halting the multiplication process of viruses.

Although the study showed a potential solution for combating HRV, more research must be done before a drug can be developed. When the drug is developed, it will need to undergo clinical trials to determine if it meets U.S. Food and Drug Administration standards for gaining approval.